unilife corp-cdi
(UNS:Australian Stock Exchange - SEATS)
unilife corp-cdi (UNS) Snapshot
|
Open
A$0.62
|
Previous Close
A$0.59
|
|
|
Day High
A$0.63
|
Day Low
A$0.62
|
|
|
52 Week High
06/13/12 - A$0.83
|
52 Week Low
04/8/13 - A$0.30
|
|
|
Market Cap
339.4M
|
Average Volume 10 Days
3.3M
|
|
|
EPS TTM
--
|
Shares Outstanding
547.4M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
unilife corp-cdi (UNS) Details
Unilife Corporation designs, develops, manufactures, and commercializes injectable drug delivery systems in the United States and internationally. The company’s principal product is the Unifill ready-to-fill syringe, which is designed for pharmaceutical manufacturers in a ready form for filling with their injectable drugs and vaccines. It also offers Unifill Syringe, a staked (fixed) retracting needle that is designed for use with liquid stable drugs; Unifill Select glass prefilled syringe, which facilitates the use of liquid stable drug or vaccine, or a diluent to reconstitute and deliver a lyophilized drug supplied in a vial; and Unitract 1mL syringes for use in healthcare facilities and by patients who self-administer prescription medication, such as insulin. In addition, the company provides Rita disposable auto-injector that is designed to inject the prefilled dose from a single Unifill syringe; and Lisa reusable auto-injector, which automates the removal of the needle shield and enhances needle insertion and retraction, as well as EZMix dual or multi-chamber prefilled syringe for the reconstitution and delivery of injectable therapies. Further, it offers the Precision-Therapy range of bolus injectors for use with bolus-based therapies that require short or long duration injections; and the Flex-Therapy range of bolus injectors for use with rate-based therapies that require infusion over a longer duration of time where the delivery rate is controlled for hours or days. Additionally, the company provides specialized device technology platforms comprising devices for targeted organ delivery, low dose delivery systems, and implant deployment systems for the administration of an implantable drug through an intravitreal or intraocular injection. Its customers also include pharmaceutical and biotechnology companies; and suppliers of combination drug-delivery devices to government agencies. The company is headquartered in York, Pennsylvania.
Last Reported Date: 09/13/12
unilife corp-cdi (UNS) Top Compensated Officers
unilife corp-cdi (UNS) Key Developments
Unilife Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. For the period, net operating cash out flows were $10,172,000 against $30,907,000 for the same period in the last year. Payment for acquisition of physical non-current assets was $610,000 against $1,931,000 for the same period in the last year. Revenues for the three months ended March 31, 2013, were $0.7 million compared to $1.3 million for the same period in 2012. The company's net loss for the three months ended March 31, 2013, was $14.1 million, or $0.17 per share, compared to a net loss of $14.9 million, or $0.21 per share, for the same period in 2012. The decrease in the net loss was primarily attributable to the reduction in research and development expenses of $1.2 million as well as a decrease in selling, general and administration expenses. Adjusted net loss for the three months ended March 31, 2013, was $9.4 million, or $0.12 per share, compared to $10.7 million, or $0.15 per share, for the same period in 2012. operating loss was $13.503 million compared to $14.305 million a year ago. For the nine months, the company reported total revenues of $2.076 million compared to $4.293 million a year ago. Operating loss was $39.417 million compared to $35.958 million a year ago. Net loss was $41.221 million compared to $37.441 million a year ago. Basic and diluted net loss per share was $0.52 compared to $0.57 a year ago. Adjusted net loss was $28.168 million compared to $26.762 million a year ago. Diluted adjusted net loss per share was $0.36 compared to $0.40 a year ago.
Unilife Corporation, Q3 2013 Earnings Call, May 09, 2013
Unilife Corporation announced that they will report Q3, 2013 results at 5:00 PM, Eastern Standard Time on May 09, 2013
| Recently Viewed | |||
| UNS:AU | A$0.62 AUD | +0.03 |  |
| Company | Last | Change |
| Insulet Corp | $29.66 USD | +0.42 |
| Retractable Technologies Inc | $1.32 USD | -0.03 |
| Terumo Corp | ¥5,290 JPY | +20.00 |
| West Pharmaceutical Services Inc | $68.42 USD | +0.73 |
| Ypsomed Holding AG | SFr.54.50 CHF | 0.00 |
| View Industry Companies | ||
Industry Analysis
UNS
Industry Average
| Valuation | UNS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 85.8x |
|
| Price/Book | 7.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 34.5x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: Apr 29
Sponsored Financial Commentaries
Sponsored Links
To contact UNILIFE CORP-CDI, please visit www.unilife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
